Vaxess Technologies, a Cambridge, MA-based life sciences company developing a shelf-stable MIMIX skin patch for vaccines and therapeutics, raised $12M in funding.
Backers included RA Capital Management, Engine Ventures, GHIC, and Mission Bio Capital. This brings Vaxess’s total equity and non-dilutive funding to more than $90M.
The company intends to use the funds to advance GLP-1, continue in vivo work with mRNA, and expand and scale manufacturing process capabilities in support of new partnerships to deliver next generation vaccines and therapeutics.
Led by Rachel Sha, Vaxess provides a MIMIX™ platform that combines a proprietary microarray patch and applicator, capable of delivering a wide range of therapies and vaccines. Advanced biomaterials used for the dissolvable microarray tips enable high levels of dose delivery control, and can be modified to deliver different payloads. Additionally, its MIMIX patch does not require refrigeration, enabling delivery to low resource settings.
Vaxess announced the appointment of Rachel Sha to CEO, as Michael Schrader steps down from the position.
FinSMEs
22/05/2024